Pegylated interferon (PEG-IFN) alpha combined with ribavirin is the current standard treatment for hepatitis C, but around 50% of patients do not respond for reasons that are not fully understood. To explore the regulation of IFN-inducible protein kinase (PKR), we have measured PKR mRNA levels in peripheral blood mononuclear cells (PBMCs) and in liver biopsies from patients with chronic hepatitis C. PBMCs were also analysed after in vitro incubation with IFN and during antiviral therapy. Non-responders to PEG-IFN plus ribavirin had pre-treatment PKR mRNA levels in PBMCs (0.1 ±0.0074) and in liver (0.102 ±0.051) that were significantly higher than those of responders (PBMCs: 0.023 ±0.014, P=0.0005; liver: 0.034 ±0.020; P=0.0002). On the other hand, PKR mRNA levels in PBMCs were similar in non-responders and in responders after in vitro exposure to IFN (0.434 ±0.301 vs 0.403 ±0.222; P=NS) and during therapy (0.31 ±0.10 vs 0.30 ±0.12; P=NS). These results indicate that in hepatitis C, non–responsiveness to IFN-alpha is associated with pre-treatment up-regulation of the PKR gene, evidence that the infecting hepatitis C virus is able to stimulate endogenous IFN production, being resistant to its antiviral effect. On the other hand, the PKR gene response to exogenous IFN was similar in responders and non-responders, at least in PBMCs, suggesting that variations in its activation are not major determinants of the outcome of antiviral treatment.
References
1.
FriedM.W., ShiffmanM.L., ReddyK.R., SmithC., MarinosG., GoncalesF.L.Jr., HaussingerD., DiagoM., CarosiG., DhumeauxD., CraxiA., LinA., HoffmanJ., & YuJ.Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.New England Journal of Medicine2002; 347: 975–982.
2.
MannsM.P., McHutchisonJ.G., GordonS.C., RustgiV.K., ShiffmanM., ReindollarR., GoodmanZ.D., KouryK., LingM., & AlbrechtJ.K.Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial.Lancet2001; 358: 958–965.
3.
NeumannA.U., LamN.P., DahariH., GretchD.R., WileyT.E., LaydenT.J., & PerelsonA.S.Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy.Science1998; 282: 103–107.
4.
NaganumaA., NozakiA., TanakaT., SugiyamaK., TakagiH., MoriM., ShimotohnoK., & KatoN.Activation of the interferon-inducible 2′-5′-oligoadenylate synthetase gene by hepatitis C virus core protein.Journal of Virology2000; 74: 8744–8750.
5.
GaleM.J.Jr., KorthM.J., TangN.M., TanS.L., HopkinsD.A., DeverT.E., PolyakS.J., GretchD.R., & KatzeM.G.Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein.Virology1997; 230: 217–227.
6.
GaleM.J.Jr., KorthM.J., & KatzeM.G.Repression of the PKR protein kinase by the hepatitis C virus NS5A protein: a potential mechanism of interferon resistance.Clinical Diagnostic Virology1998; 10: 157–162.
7.
GaleM.Jr., BlakelyC.M., KwieciszewskiB., TanS.L., DossettM., TangN.M., KorthM.J., PolyakS.J., GretchD.R., & KatzeM.G.Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation.Molecular & Cellular Biology1998; 18: 5208–5218.
8.
DelhemN., SabileA., GajardoR., PodevinP., AbadieA., BlatonM.A., KremsdorfD., BerettaL., & BrechotC.Activation of the interferon-inducible protein kinase PKR by hepatocellular carcinoma derived-hepatitis C virus core protein.Oncogene2001; 20: 5836–5845.
9.
TaylorD.R., TianB., RomanoP.R., HinnebushA.G., LaiM.M., & MathewsM.B.Hepatitis C virus envelope E2 does not inhibit PKR by simple competition with autophosphorylation sites in the RNA-binding domain.Journal of Virology2001; 75: 1265–1273.
10.
PflugheberJ., FredericksenB., SumpterR., WangC., WareF., SodoraD.L., & GaleM.Regulation of PKR and IRF-1 during hepatitis C virus RNA replication.Proceedings of the National Academy of Sciences, USA2002; 99: 4650–4655.
11.
FoyE., LiK., WangC., SumpterR., IkedaM., LemonS.M., & GaleM.Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease.Science2003; 300: 1145–1148.
MurashimaS., KumashiroR., IdeT., MiyajimaI., HinoT., KogaY., IshiiK., UenoT., SakisakaS., & SataM.Effect of interferon treatment on serum 2′,5′-oligoadenylate synthetase levels in hepatitis C infected patients.Journal of Medical Virology2000; 62: 185–190.
14.
PodevinP., GuechotJ., SerfatyL., Monrand-JoubertL., VeyrunesC., BonnefisM.T., & PouponR.Evidence for a deficiency of interferon response in mononuclear cells from hepatitis C viremic patients.Journal of Hepatology1997; 27: 265–271.
15.
AntonelliG., SimeoniE., TurrizianiO., TesoroR., RedaelliA., RoffiL., AntonelliL., PistelloM., & DianzaniF.Correlation of interferon-induced expression of MxA mRNA in peripheral blood mononuclear cells with the response of patients with chronic active hepatitis C to IFN-alpha therapy.Journal of Interferon Cytokine Research1999; 19: 243–251.
16.
PawlotskyJ.M., HovanessianA.G., Roudot-ThoravalF., RobertN., BouvierM., BabanyG., DuvalJ., & DhumeauxD.Effect of alpha interferon (IFN-alpha) on 2′-5′ oligoadenylate synthetase activity in peripheral blood mononuclear cells of patients with chronic hepatitis C: relationship to the antiviral effect of IFN-alpha.Antimicrobial Agents & Chemotherapy1996; 40: 320–324.
17.
FreseM., PietschmannT., MoradpourD., HallerO., & BartenschlagerR.Interferon-alpha inhibits hepatitis C virus subgenomic RNA replication by an MxA-independent pathway.Journal of General Virology2001; 82: 723–733.
18.
AsahinaY., IzumiN., UchiharaM., NoguchiO., NishimuraY., InouneK., UedaK., TsuchiyaK., HamanoK., ItakuraJ., & MiyakeS.Interferon-stimulated gene expression and hepatitis C virus dynamics during different interferon regimens.Journal of Hepatology2003; 39: 421–427.
19.
MacQuillanG.C., MammotteC., ReedW.D., JeffreyG.P., & AllanJ.E.Upregulation of endogenous intrahepatic interferon stimulated genes during chronic hepatitis C virus infection.Journal of Medical Virology2003; 70: 219–227.
20.
MacQuillanG.C., de BoerW.B., PlattenM.A., McCaulK.A., ReedW.D., JeffreyG.P., & AllanJ.E.Intrahepatic MxA and PKR protein expression in chronic hepatitis C virus infection.Journal of Medical Virology2002; 68: 197–205.
21.
McHutchisonJ.G., MannsM., PatelK., PoynardT., LindsayK.L., TrepoC., DienstagJ., LeeW.M., MakC., GaraudJ.J., & AlbrechtJ.K.; International Hepatitis Interventional Therapy Group. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.Gastroenterology2002; 123: 1061–1069.
22.
DavisG.L.Monitoring of viral levels during therapy of hepatitis C.Hepatology2002; 36: S145–151.
23.
PatersonM., LaxtonC.D., ThomasH.C., AckrillA.M., & FosterG.R.Hepatitis C virus NS5A protein inhibits interferon antiviral activity, but the effects do not correlate with clinical response.Gastroenterology1999; 117: 1187–1197.
24.
HijikataM., MishiroS., MiyamotoC., FuruichiY., HashimotoM., & OhtaY.Genetic polymorphism of the MxA gene promoter and interferon responsiveness of hepatitis C patients: revisited by analyzing two SNP sites (-123 and -88) in vivo and in vitro.Intervirology2001; 44: 379–382.
25.
FernandezM., QuirogaJ.A., MartinJ., HerreroM., PardoM., HorisbergerM.A., & CarrenoV.In vivo and in vitro induction of MxA protein in peripheral blood mononuclear cells from patients chronically infected with hepatitis C virus.Journal Infectious Diseases1999; 180: 262–267.
26.
MeierV., MihmS., & RamadoriG.MxA gene expression in peripheral blood mononuclear cells from patients infected chronically with hepatitis C virus treated with interferon-alpha.Journal of Medical Virology2000; 62: 318–326.
27.
BallardiniG., GroffP., PontissoP., GiostraF., FrancesconiR., LenziM., ZauliD., AlbertiA., & BianchiF.B.Hepatitis C virus (HCV) genotype, tissue HCV antigens, hepatocellular expression of HLA-A, B, C, and intercellular adhesion-1 molecules. Clues to pathogenesis of hepatocellular damage and response to interferon treatment in patients with chronic hepatitis C.Journal of Clinical Investigation1995;.
